Leading healthcare and pharmaceuticals firm GlaxoSmithKline (GSK) and Pfizer have announced plans to merge their respective consumer health businesses in a move that will see GSK separate to create two new global companies. GSK said it would have a majority controlling equity interest of 68% in the joint venture, which has combined sales of approximately £9.8 billion ($12.7 billion) and will bring brands such as Sensodyne, Voltaren and Panadol together with Advil, Centrum …
Loading tweets...
GlaxoSmithKline
FMCG giant Unilever has announced it has secured a deal to acquire GSK’s health consumer products division in India, Bangladesh and other predominantly Asian markets, for a total consideration of €3.3 billion ($3.8 billion). The transaction is said to consist of an all-equity merger of Hindustan Unilever Ltd with GSK Consumer Healthcare India, the acquisition of an 82% stake in GSK Bangladesh Limited, and the acquisition of certain other commercial operations and assets outside India. …
GlaxoSmithKline (GSK), the UK based healthcare multinational, is to buy out its stake in its consumer healthcare venture with Novartis at a cost of $13 billion. The joint venture, which includes the toothpaste brand Sensodyne and painkiller brand Panadol, as well as Nicotinell stop smoking aids, was formed in 2015 as part of Novartis’ portfolio transformation, which comprised a three-part inter-conditional transaction with GSK, including the combination of the Novartis …
Copyright © 2017. Gama. All rights reserved. Privacy Policy | Legal Notice
GlaxoSmithKline Archives - Gama